AJP Asia Intelligence Agency

Alteogen Shares Plunge Amid Patent Dispute Concerns

Alteogen's stock is experiencing a sharp decline early in the trading session.


As of 9:27 a.m., Alteogen shares have fallen by 25,300 won (-12.57%) to 175,200 won compared to the previous trading day.


The stock initially dropped to 173,200 won before recovering to the 200,000 won range, only to face renewed pressure, reflecting significant volatility.


Due to the widening price fluctuations, the Korea Exchange activated a volatility control mechanism for the stock at around 9:10 a.m.


The sharp decline is attributed to concerns over potential disruptions in the supply of Alteogen's subcutaneous formulation of the drug Keytruda SC (active ingredient: pembrolizumab) amid escalating patent disputes in the U.S. and Europe.


Previously, a Dutch court ruled that Keytruda SC infringes on a European patent held by U.S.-based Halozyme, leading to restrictions on manufacturing and sales in eight countries, including the Netherlands, Belgium, Denmark, France, Ireland, Italy, Sweden, and Switzerland.





* This article has been translated by AI.